Inhibrx Biosciences, Inc. (INBX) Cash Flow Statement
Inhibrx Biosciences, Inc. (INBX) generated -$131.9M of operating cash flow over the twelve months to 2026-06-30, spent $10000 on capital expenditure and had free cash flow of -$131.9M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
INBXInhibrx Biosciences, Inc.Follow INBX — free
—
Price chart with a free account
- Market cap
- 1.4B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 13 Nov, in 20 days
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Operating cash flow | -194.4 | -129.8 | -131.9 | |
| Capital expenditure | 2.6 | 0.0 | -0.0 | |
| Free cash flow | -197.0 | -129.8 | -131.9 | |
| Stock-based compensation | 58.5 | 11.1 | — |
USD millions · SEC XBRL
Inhibrx Biosciences, Inc. — questions
- What is Inhibrx Biosciences, Inc.'s operating cash flow?
- -$131.9M over the twelve months to 2026-06-30.
- How much does Inhibrx Biosciences, Inc. spend on capital expenditure?
- $10000 over the twelve months to 2026-06-30.
- What is Inhibrx Biosciences, Inc.'s free cash flow?
- -$131.9M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Inhibrx Biosciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.